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Abstract
Ovine epididymitis (Brucella ovis) has been assessed according to the criteria of the Animal Health Law
(AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of
ovine epididymitis to be listed, Article 9 for the categorisation of ovine epididymitis according to
disease prevention and control rules as in Annex IV and Article 8 on the list of animal species related
to ovine epididymitis. The assessment has been performed following a methodology composed of
information collection and compilation, expert judgement on each criterion at individual and, if no
consensus was reached before, also at collective level. The output is composed of the categorical
answer, and for the questions where no consensus was reached, the different supporting views are
reported. Details on the methodology used for this assessment are explained in a separate opinion.
According to the assessment performed, ovine epididymitis can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL. The disease would comply with the criteria
as in Sections 3, 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and
control rules referred to in points (c), (d) and (e) of Article 9(1). The animal species to be listed for
ovine epididymitis according to Article 8(3) criteria are mainly sheep and other species of the families
Bovidae and Cervidae as susceptible and sheep and deer as reservoirs.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on ovine epididymitis (Brucella ovis)
according to the criteria of the AHL articles as follows:
• Article 7: ovine epididymitis proﬁle and impacts
• Article 5: eligibility of ovine epididymitis to be listed
• Article 9: categorisation of ovine epididymitis according to disease prevention and control rules
as in Annex IV
• Article 8: list of animal species related to ovine epididymitis
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of ovine epididymitis (Brucella ovis) according to the Article 7
criteria of the AHL and related parameters (see Table 2 of the opinion on methodology (EFSA AHAW
Panel, 2017)), based on the information contained in the fact sheet as drafted by the selected disease
scientist (see Section 2.1 of the scientiﬁc opinion on the ad hoc methodology) and amended by the
AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
The disease affects sheep exclusively, causing genital lesions and overall reproductive failure. It is
caused by Brucella ovis, a Gram-negative and naturally rough (R) bacterium belonging to the genus
Brucella. It has been historically misnamed as ‘ovine epididymitis’ and also ‘ram epididymitis’ or
‘contagious epididymitis’. However, as B. ovis infection can produce epididymitis in rams but also other
clinical signs in both male and female sheep (as for example placentitis and abortion), and moreover,
epididymitis in rams can be caused by a large variety of pathogenic agents (for a review see Blasco
(1990, 2010), the term ‘Brucella ovis infection’1 is the preferred notation to properly denominate this
disease. Accordingly, this latter denomination will be used throughout the document.
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Natural infection has been mainly proven in domestic sheep; however, outbreaks have also been
reported in farmed white-tailed deer (Odocoileus virginianus) reared in direct contact with infected
sheep (Bailey, 1997).
1 ‘Brucella ovis infection’ is preferred to ‘Ovine epididymitis’ a non-speciﬁc lesion that can be due to many other organisms.
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Parameter 2 – Naturally susceptible domestic species (or family/orders)
The natural infection appears mainly in sheep; however, experimental inoculation of B. ovis in male
goats leads to both genital and extragenital colonisation in some animals, inducing subsequent
pathological lesions like those produced in infected rams (Garcıa-Carrillo et al., 1977; Burgess et al.,
1985). In extensive breeding systems, goats and sheep are frequently managed together and,
therefore, transmission from sheep to goats and vice versa could occur. However, isolation of B. ovis
from natural cases of infection in goats has never been reported.
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Transmission to red deer (Cervus elaphus elaphus) has been proven experimentally (Ridler et al.,
2000), but since infection seems to be self-limiting in the majority of stags exposed, it remains unclear
if B. ovis infection can be sustained naturally in wild deer populations (Ridler et al., 2012).
Moreover, the infection has been suspected in bighorn sheep (Ovis canadensis canadensis), and
these animals have proven susceptible to experimental infection, developing pathological signs
characteristics of B. ovis infection including abortion, epididymitis and testicular swelling (McCollum
et al., 2013). Moreover, mouﬂon (Ovis musimon) have been suspected of being affected, and
experimental infection studies have been conducted. However, bacterial cultures after exposure were
always negative, and no pathological lesions were evidenced after both clinical and histological
examinations (Cerri et al., 2002).
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
There are few references on experimental infections of domestic animals other than sheep. As
commented above, experimental inoculation of B. ovis in male goats leads to genital and extragenital
colonisation and development of lesions similar to those observed in naturally infected rams.
Several small laboratory animal species have been experimentally inoculated with B. ovis by a
variety of routes, and doses, with varying success. At least rabbits, rats, gerbils, hamsters, guinea pigs
and mice can be experimentally infected with B. ovis (for a review see Blasco (2010)).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
No wild species have been proven as a natural reservoir of B. ovis. Despite that, white-tailed and
red deer sharing infected environments and reared under captivity with domestic sheep can result in
infection, it is unclear if these wild species could sustain the infection and spread B. ovis in the
environment in the absence of sheep.
Parameter 6 – Domestic reservoir species (or family/orders)
No domestic species other than sheep have been proven as a reservoir of B. ovis.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/ Incidence
B. ovis is found in sheep-raising regions worldwide and successful examples of eradication (in the
whole country – see Section 3.1.4) have never been reported (Blasco, 2010). As B. ovis infection is not
submitted to compulsory eradication programmes in any country of the world (perhaps with the
exception of important areas of Australia and New Zealand), the ofﬁcial reporting data are scanty and
largely incomplete.
The precise situation and distribution of this infection worldwide are largely unknown. B. ovis
infection has been reported in most countries in America, Europe, Africa and Asia as well as Australia
and New Zealand, but probably occurs in most – if not all – sheep-raising countries. Only few countries
report suitable data proving that the infection has never been reported in Belgium, Denmark, Finland,
Greece, Ireland, Luxembourg, Portugal, Sweden, the Netherlands and the UK (AQIS, 2000).
Nevertheless, there is no ofﬁcially free status in EU directives for B. ovis, only some testing requirements
for movements between Member States for some animal categories (e.g. animals for breeding) exist.
The prevalence and incidence in domestic na€ıve sheep populations which are neither vaccinated nor
submitted to any ofﬁcial sanitary intervention are usually very high and depend largely on the time
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elapsed after the onset of disease in a given ﬂock. The prevalence, both apparent (serological) and
bacteriologically proven, is highly variable when the disease is ﬁrst reported in a country, with 2–67%
of rams infected and 9–50% of ﬂocks affected (Blasco, 1990; Sergeant, 1994). The collective and
individual prevalence reported in the Basque Country in Spain, before implementing any control
programme were 9.66% (3695 ﬂocks tested) and 5.33% (9805 rams tested), respectively (Blasco,
2002). In these initial stages, yearly incidences approach prevalence values or can be slightly lower. In
countries applying some degree of control programme (based essentially on vaccination with the Rev.1
vaccine and/or testing and culling), the prevalence is much lower, but complete eradication is
extremely difﬁcult to achieve. In fact, no country has succeeded in a complete eradication of this
infection (see Section 3.1.4.6 Parameter 2). When control interventions are applied, the prevalence/
incidence ﬁgures are lower but also highly variable depending on the countries and the characteristics
and degree of application of the control programmes implemented. Suitable information on these
parameters is not available in Member States (MSs) in which no ofﬁcial control and eradication
programmes are performed regularly. However, partial data (See Section 3.1.4.6 Parameter 2) prove
that control measures can reduce signiﬁcantly the prevalence.
B. ovis natural infection has never been reported in wildlife species (see Section 3.1.1); thus, the
prevalence is considered null (zero).
Parameter 2 – Case morbidity rate (% clinically diseased animals out of infected ones)
Suitable data on the natural morbidity rate of B. ovis infection in sheep are scanty. In naturally
infected na€ıve ﬂocks, the proportion of clinical lesions in infected rams can be 20–50% and abortions
in ewes 25–60%. Affected ﬂocks are also affected by an overall reduced fertility (Blasco, 1990, 2010).
The morbidity rate depends mainly on the route of infection, the infecting dose, the assessment
procedure, and of intrinsic characteristics of the animals such as the age and breed. Experimental
doses of around 5 9 109 colony forming units (CFU) applied via intraconjunctival route and/or
intrapreputially induce infection rates close to 100% among inoculated animals (Blasco, 1990, 2010).
In that artiﬁcially infected population, the percentage of clinically affected rams detected by testicular
palpation ranges from 30% to 50%. However, when the main target organs (epididymides, seminal
vesicles and bulbourethral glands) are inspected microscopically, 90–100% of rams are found
pathologically affected (Blasco, 2010).
The infection has been demonstrated in young lambs, suggesting that animals at, or soon after
puberty, are susceptible to B. ovis. However, it has been reported repeatedly that the incidence of
both testicular alterations and B. ovis prevalence increases with the age of rams, being this related to
sexual experience (Blasco, 1990). It has been hypothesised that susceptibility to infection may vary
among breeds of sheep, with Merino breeds less frequently infected than British breeds reared in the
same environment (Clapp et al., 1962). Moreover, Spanish native and Merino-derived breeds seem to
be more resistant to infection than other European breeds. Although genetic resistance could be
important, it has been suggested that susceptibility to infection could also relate to differences in
growth rates and sexual precocity and activity (Blasco, 1990).
It is a widespread misconception that only rams are involved in maintaining and spreading the
infection and that ewes do not play a relevant role in the epidemiology. In fact, it has been reported
that after being mated by infected rams, only few ewes develop an active infection leading to abortion
and dead or weak lambs (Clapp et al., 1962). However, in contrast with experimental infection trials in
ewes in which only few lymph nodes and organs were found infected (Muhammed et al., 1975), a
widespread infection has been induced after experimental challenge in ewes (Grillo et al., 1999). In
this latter study, the uterus and the iliac and supramammary lymph nodes were the main target
organs of B. ovis and related to the high percentage of ewes that persistently excreted B. ovis by the
vaginal route (over 80%) and milk (over 60%). Surprisingly, despite the severe endometritis induced in
most of exposed ewes, none aborted and only few gave birth to stillborn lambs (Grillo et al., 1999).
These clinical ﬁndings concur with those obtained in similar trials conducted in pregnant ewes
demonstrating that, despite the induction of severe endometritis, B. ovis seems to have a relatively
low capacity to induce abortion in sheep (for a review see Blasco (2010)).
Mortality
Parameter 3 – Case fatality rate
The case fatality rate in naturally or experimentally induced B. ovis infections in domestic, wild or
laboratory animals is considered to be very low or null. No mortality cases have been evidenced when
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naturally or experimentally infected animals are maintained for a given period of time (usually short).
However, no naturally or experimentally infected animals have been maintained for signiﬁcantly long
periods – i.e. years – to determine if the infection can produce lethal complications as a consequence
of abscess in testicles and secondary infections by other bacteria. In any case, it is assumed and
widely accepted to be null or very low.
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
Human cases due to B. ovis have never been reported, and this infection is considered as non-
zoonotic.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
The absence of plasmids and lysogenic phages in the Brucella genus (Moreno, 1998) explains
probably why antibiotics do not play a signiﬁcant selective role in any Brucella species as compared
with other bacterial pathogens. Moreover, due to economical, epidemiological and public health
reasons, brucellosis treatment has been precluded in domestic animals; this has also probably limited
the potential development of antibiotic resistance. Accordingly, resistance is not considered a
signiﬁcant issue in treating both animal and human brucellosis (Maves et al., 2011).
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
B. ovis remains conﬁned to the lymph nodes close to entry sites for 2–3 weeks and then reach blood
via the efferent lymph, and bacteraemia leads to a generalised infection in reticuloendothelial organs,
lymph nodes distant from entry sites, and the genital and extragenital organs and accessory sexual
glands. The precise duration of B. ovis infection has not been properly established and it is accepted
that only a low proportion of infected animals develop a self-cure mechanism, but most remain infected
for life, excreting the bacteria intermittently and spreading the infection (Blasco, 1990, 2010).
Parameter 2 – Presence and duration of latent infection period
While the existence of latent infections has been evidenced in other Brucella species, this
phenomenon has not been yet proven in the case of B. ovis infection in sheep.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
Latent infections have never been reported in the case of B. ovis infection. Although many lambs
are born to ewes with severe placental damage and suckle B. ovis-infected milk throughout lactation,
only very few are found to be heavily infected (Grillo et al., 1999). Several factors can be considered
to explain this relatively low infective capacity of B. ovis for lambs and the absence of induced latent
infections. First, it is widely accepted that newborn lambs are relatively non-reactive to brucellae.
Second, it could be possible that the speciﬁc anti-B. ovis antibodies present in colostrum help to
abrogate B. ovis infection in suckling lambs. Finally, the low pathogenicity of B. ovis relative to that of
smooth (S) brucellae could also be considered (Blasco, 2010).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
In contrast with some S Brucella species, no studies have been conducted to determine the precise
environmental persistence of B. ovis. Taking this caveat into account, some S Brucella species can
survive for long periods under environmental conditions, and this could also be the case of B. ovis.
Dryness, high temperatures and direct sunlight exposure are very unfavourable for Brucella survival.
On the other hand, in favourable conditions like pH >4, cool temperature, high humidity and the
absence of direct sunlight, Brucella spp. may survive for relatively long periods in aborted fetuses and
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fetal membranes, faeces and liquid manure, water, wool and hay as well as on equipment and clothes.
Brucella spp. are able to withstand drying, particularly in the presence of organic material, and can
then remain viable in dust and soil for relatively long periods. Survival is prolonged at low
temperatures, especially in snow and ice.
Since the presence of DNA in selected matrixes or the environment is not representative of the true
survival ability of Brucella, no comments will be made on this particular topic.
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Passive ram-to-ram venereal transmission via the ewe is considered the most important way of
spreading the infection. However, ram-to-ram transmission can also happen by direct contact between
infected and healthy rams through sodomy and mucosal routes (Blasco, 1990, 2010), via orogenital
transmission by bucks (rams, stags) licking the preputial area of infected rams (Ridler et al., 2000).
Direct ewe-to-ram venereal transmission is considered infrequent. Although uterine infection is
characteristic in both natural and experimental infections in ewes (Collier and Molello, 1964; Marco
et al., 1994; Grillo et al., 1999), it has been considered classically that only few ewes develop an active
infection leading to abortion and dead or weak lambs after being mated by infected rams, thus playing
a minor role in transmission. However, in contrast with previous trials in which only few (Muhammed
et al., 1975) or no (Collier and Molello, 1964) lymph nodes or extragenital organs became infected, a
widespread infection has been reported after suitable B. ovis experimental exposure in ewes (Grillo
et al., 1999). In this latter study, the uterus and iliac and supramammary lymph nodes were the main
target organs, which explains the high percentage of ewes excreting B. ovis by the vaginal route. This
represents a potential risk of transmission from ewe to ewe and also from ewes to rams in the ﬁeld.
Surprisingly, but as reported previously, despite the high challenge dose and the severe endometritis
induced in most ewes, none aborted and only few gave birth to stillborn lambs (Grillo et al., 1999).
Environmental contamination with B. ovis due to abortions or the vaginal secretions may facilitate the
spreading to both ewes and rams, nonetheless because of the low frequency of these events and the
minimal infectious dose required, there is a very low probability that the environment (e.g. water) could
be a source of infection. In addition, lambs born to infected ewes seldom develop active infection and
they do not do so even after nursing on contaminated milk (Grillo et al., 1999). Milk excretion of B. ovis
has also been considered classically as a very rare event. However, most experimentally infected ewes
develop a mammary infection characterised by a heavy and persistent (at least two successive
lactations in some animals) excretion of B. ovis in milk (Grillo et al., 1999). Placental damage and milk
excretion could be of relevance in the maintenance of infection via vertical route to the fetus and
through perinatal transmission to suckling lambs with the possibility of developing latent infections
(possible but never reported). Altogether, the role played by the ewes in spreading the infection from
ram to ram and potentially from ewe to ewe may explain in part the failure of control programmes
based exclusively on testing and culling the seropositive rams (Marco et al., 1994).
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
B. ovis has never been proven to be transmitted to humans.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
Data on the incidence of animal brucellosis have been commented above (see Section 3.1.1.2) and
are extended in Section 3.1.1.7, Parameter 2. Despite the widespread absence of data, it has been
proven that in infected environments and in the absence of suitable control programmes, the risk of
transmission of B. ovis between animals includes high transmissibility.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
Several R0 values ranging between 1 and 3 have been reported empirically or hypothesised for
brucellosis in ruminants caused by S Brucella species, but these ﬁgures are not straightforward
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because transmission dynamics is complicated by multiple interactions (Beauvais et al., 2016; Hou and
Sun, 2016). No precise R0 ﬁgures have been established for B. ovis infection.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, where the disease is not present in the Union, the risk of its introduction
into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in the EU
Since control and eradication programmes are not compulsory, precise and ofﬁcially updated data
on the distribution and current prevalence of B. ovis infection are lacking in the MS countries. The
infection has been reported in at least Austria, Bulgaria, Croatia, the Czech Republic, France, Germany,
Hungary, Italy, Romania, Serbia and Spain, but it is probable that other European countries have been
or are currently affected also (Blasco, 2010). The infection has never been reported in Belgium,
Denmark, Finland, Greece, Ireland, Luxembourg, Portugal, Sweden, the Netherlands and the UK
(AQIS, 2000).
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
As indicated above, no ofﬁcially updated reports exist in the MS on the presence, distribution and
epidemiological occurrence of ovine brucellosis due to B. ovis. However, the infection by B. ovis is
probably endemic in many MS countries, causing sometimes epidemic outbreaks. After many years of
implementation of control programmes against Brucella melitensis infection in sheep (most based on
the use in both male and female sheep of the live B. melitensis Rev.1 vaccine – which confers cross-
protection against B. ovis), the epidemiological occurrence of B. ovis infection was becoming sporadic
at least in several MS (for example, France and Spain). However, once the infection by B. melitensis
has been controlled or eradicated in these MS, and then, the Rev.1 vaccination banned; the prevalence
of B. ovis infection has increased dramatically, causing important epidemic outbreaks in some areas. As
an example, the number of B. ovis infected ﬂocks has increased signiﬁcantly in some regions in
France, since Rev.1 vaccination was forbidden in 2008 (Praud et al., 2012; Picard-Hagen et al., 2015).
Thus, it can be concluded that there is a clear ofﬁcial under-reporting and an overall lack of awareness
of this infection in the MS. Unless ofﬁcial control programmes be implemented, it is expected that the
overall prevalence in the currently infected EU MS will increase exponentially.
Risk of introduction
The disease is already present in the EU.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Brucella ovis infection lacks pathognomonic symptoms and its diagnosis is based on the existing
direct and indirect tests, as indicated by OIE (Table 1), the latter being those applied routinely in
surveillance and control and eradication programmes. Detailed information of the availability, feasibility
and effectiveness of the diagnostic tests is given below in Section 3.1.4.1.
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Control tools
Parameter 2 – Existence of control tools
Selective breeding for generating disease-resistant genotypes could be theoretically feasible as a
control strategy over a prolonged time (Morris, 2007). However, no speciﬁc control programmes have
been yet developed for animal brucellosis on this genetic basis.
Two possible strategies can be applied to control B. ovis infection. One could be based on a mass
vaccination with Rev.1 vaccine (applied to both males and females). Although feasible theoretically, this
programme has never been applied regularly in any country, probably due to: (i) the banning of Rev.1
in B. melitensis ofﬁcially free countries (most EU MS), (ii) the serological interference caused in
B. melitensis diagnostic tests and (iii) the unclear cost–beneﬁt ratio. The second strategy (that
currently applied in most countries) is an eradication programme based on test and slaughter,
combined (infrequently) or not with vaccination (applied in young replacements exclusively). Rev.1 is
the only effective vaccine available against B. ovis. Extended comments on feasibility, availability and
efﬁcacy of this vaccine are made in Section 3.1.4.2.
It is believed that the simplest way to reduce B. ovis prevalence is the culling of rams showing
palpable testicular alterations. However, this is not adequate because of the existence of infected rams
lacking lesions and of infected ewes as both constitute a risk. Eradication can be achieved by the
combined use of scrotal palpation and complement ﬁxation test (CFT) serological testing, both tests
performed every 6 months, then culling both the clinically affected and the serologically positive rams
(Blasco, 2010). Of similar diagnostic value, the agar gel immunodiffusion (AGID) test is more practical
than the CFT for such purpose. Although there is limited information, when the enzyme-linked
immunosorbent assay (ELISA) is combined with either the CFT or the AGID, an improvement of the
Table 1: Main purpose of OIE methods available for the diagnosis of B. ovis infection in sheep
(adapted from OIE (2016)).
Method
Purpose
Population
freedom
from
infection
Individual
animal
freedom
from infection
prior to
movement(a)
Contribute to
eradication
policies(b)
Conﬁrmation
of clinical
cases(c)
Conﬁrmation
of suspect
cases(d)
Flock
prevalence
of infection –
surveillance
Agent identiﬁcation
Staining
methods
 – – + – –
Culture – – – +++ +++ –
PCR(e) – – – + + –
Detection of immune response
Complement
ﬁxation
test (CFT)
+++ ++ ++ ++ ++ ++
ELISA +++ ++ ++ ++ ++ ++
Agar gel
immune
diffusion
(AGID)
++ ++ ++ ++ ++ ++
+++ = recommended method; ++ = suitable method; + = may be used in some situations, but cost, reliability or other factors
severely limits its application; – = not appropriate for this purpose; n/a = not applicable. PCR = polymerase chain reaction;
CFT = complement ﬁxation test; ELISA = enzyme-linked immunosorbent assay; AGID = agar gel immunodiffusion test.
(a): This applies only to ﬂocks, countries or zones free from infection with Brucella ovis.
(b): To improve the efﬁciency of eradication policies in infected ﬂocks, it is recommended to associate tests in parallel to increase
the sensitivity of the diagnosis, i.e. two serological tests at least, e.g. CFT (or AGID) and I-ELISA.
(c): In low-prevalence or almost free zones, the predictive value of positive results to serological tests may be very low. In such
situation, the agent identiﬁcation is usually needed for conﬁrming clinical cases.
(d): In infected ﬂocks, any reactor in any serological test should be considered as infected.
(e): No internationally accepted method exists and both false-positive and false-negative results may occur.
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efﬁcacy of control programmes based on a single test would be expected (Praud et al., 2012).
Although effective in most cases, this culling programme applied in rams exclusively has failed in some
cases (Marco et al., 1994). However, B. ovis can be present in a certain proportion of ewes in ﬂocks
subjected to exclusive ram culling programmes, and in which B. ovis could not be eradicated (Marco
et al., 1994). Although the precise mechanism of transmission could not be established properly, the
maintenance of infection in these ﬂocks was most probably due to the infected ewes (Marco et al.,
1994). Therefore, in these ‘problem ﬂocks’, ewes should also be included in any control programme
against B. ovis. The same caveat should be considered when applying any control programme based
on vaccination.
No compulsory control/eradication policy is currently applied in any EU MS, and the only control
tests applied ofﬁcially are those directly related to the international trade of live sheep.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
This topic has been commented in Section 3.1.1.7.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
There are very few well-documented studies on the production losses and the economic impact of
brucellosis that take into account all aspects of the disease susceptible of affecting the animal industry.
In general, the direct production losses due to animal brucellosis have been estimated empirically and
focused essentially for brucellosis in cattle (B. abortus infection). However, precise economic
information in the case of B. ovis infection is scanty and incomplete.
Direct ﬁnancial losses are principally due to a drop in fertility, with a high replacement rate of both
rams and ewes, and which are commonly reported in infected ﬂocks (Blasco, 1990, 2010). One study
conducted in New Zealand (Liberona and Christiansen, 1983) estimated the cost of infection in 359
New Zealand dollars (NZD) per infected ram (124 NZD corresponding to fertility loss, 39 NZD to
decreased useful life and 196 NZD to increased proportion ram/ewes).
This estimated amount has been even far exceeded (Table 2) in another study conducted also in
New Zealand (Carpenter et al., 1987).
However, the above studies excluded the costs due to the infection in ewes as well as other costs in
lambs. The abortion rate in ewes and the perinatal mortality varies from 0% to 8% according the
different experimental studies (Blasco, 2010). Furthermore, it has been estimated that lambs born in the
second and third cycles as a consequence of infertility are 10–20 pounds lighter at weaning, which can
represent a loss of 10–20 USD/lamb for each cycle missed (Lamb Epididymitis: Kimberling et al. (2010)).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Human cases due to B. ovis have never been reported, and this infection is considered as
non-zoonotic.
Table 2: Main costs per ram and per year (New Zealand dollars, NZD) estimated in New Zealand in
an average B. ovis-infected ﬂock composed of 2,500 ewes and 100 rams (Carpenter et al.,
1987)
Main costs NZD estimate/infected ram/year
Decrease of the useful life of each ram 155
Decrease of production (fecundity) 302
Transmission of new cases 605
Premature culling 82
TOTAL 1,144
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3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
As it happens in other species brucellosis caused by other Brucella species, ovine brucellosis caused
by B. ovis is considered as a major contributor to animal suffering, causing fever, genital lesions,
abortions, stillbirths and the birth of weak offspring, with the ensuing increase of perinatal mortality.
Despite its relatively low abortifacient ability, B. ovis-aborted ewes may retain the placenta and
develop endometritis and infertility. Orchitis, epididymitis and inﬂammation of accessory sexual glands
are the most frequent clinical signs affecting rams and may result also in total or partial infertility
(Blasco, 1990, 2010). Deaths are very rare, except in the fetus or newborn lambs, as a consequence
of fetal subnutrition due to placentitis. Studies on the precise impact of B. ovis infection on sheep
welfare beyond the clinical signs described above are lacking.
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
In the EU, B. ovis infection has never been reported in wild animals. The infection has been
reported exclusively in non-Member States (see Section 3.1.1) in white-tailed deer and red deer reared
in direct contact with infected sheep. However, these wild animals are considered occasional dead-end
hosts of a disease transmitted from infected sheep rather than a true reservoir (Ridler et al., 2012).
Moreover, the infection is non-lethal in these wild species, which appear as of ‘least concern’ in the
IUCN list.
Parameter 2 – Mortality in wild species
Brucellosis is a non-fatal disease; thus, this issue is of minor concern.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
With the exception of the white-tailed deer and red deer species reported to be affected in
exceptional circumstances, B. ovis infection has never been reported in wild animals. Thus, the
capacities of this pathogen to persist in the environment and cause mortality in wildlife have to be
considered as negligible.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Brucella ovis can be easily cultured from infected animals or obtained from culture type strain
international suppliers. Also, these bacteria can be transferred, multiplied and stored easily. However,
an intentional or accidental contamination of food or water with B. ovis should not pose any signiﬁcant
threat for human beings and could cause only a moderate economic impact in the local sheep industry.
Altogether, these characteristics make this pathogen a non-attractive candidate to be used as a
potential agent for biological warfare purposes.
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
The main species included in the Brucella genus (including B. ovis) are listed in OIE/CFSPH
classiﬁcation (CFSPH, 2016).
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
The pathogenic brucellae for humans are included in the Encyclopaedia of Bioterrorism Defence of
Australia Group. However, as B. ovis has not been proven pathogenic for humans, it is not included
(The Australia Group, 2017).
Parameter 3 – Included in any other list of potential bio-agroterrorism agents
The pathogenic brucellae for humans are speciﬁed in the select agent rules implemented by USDA
APHIS and the Centers for Disease Control and Prevention (CDC) of the Department of Health and
Human Services (HHS) of the US. However, B. ovis is not included in that list (CRS, 2007).
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3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
Several diagnostic tests are available, recognised by the OIE and the EU, and used for surveillance/
eradication worldwide (OIE, 2016). These OIE tests and their main applications have been summarised
above in Table 1.
Since only a moderate proportion of infected rams show palpable genital lesions, and many other
infectious agents can induce epididymitis in rams (Actinobacillus seminis, Actinobacillus
actinomycetemcomitans, Histophilus ovis, Haemophilus spp., Corynebacterium pseudotuberculosis ovis
and Chlamydia psittaci, among others – for a review see Blasco (2010)), the disease cannot be
diagnosed on the exclusive basis of testicular palpation. Direct bacteriological isolation, if positive, is
the most speciﬁc diagnostic test for the conﬁrmation of the disease. Despite their usefulness for
identiﬁcation and typing, molecular tests are not fully suitable for direct diagnosis from ﬁeld samples,
and serology is the most adequate diagnostic alternative at population level, and used regularly for a
presumptive diagnosis or for surveillance. The most effective and widely used serological tests are the
CFT, the double AGID test and the indirect ELISA. The CFT is the only test currently recognised by the
OIE and the EU for certifying individual animals for international trade. However, it has been proven
that the AGID test shows similar sensitivity to the CFT, and it is a much simpler test to perform
(Blasco, 1990, 2010). Moreover, although international standardisation is lacking, numerous
independent validation studies have shown that the ELISA is more sensitive than either the CFT or
AGID test (Blasco, 2010; Praud et al., 2012). In the absence of internationally agreed standardisation
rules, the ELISA and AGID tests should be validated against a panel of appropriate positive and
negative gold standard sera (OIE, 2016).
Effectiveness
Parameter 2 – Sensitivity and Speciﬁcity of diagnostic test
The bacteriological culture (if positive) is the only unequivocal method to identify an infected
animal, but is cumbersome and needs a suitable combination of selective media and samples for
optimal sensitivity (Blasco, 2010; De Miguel et al., 2011; OIE, 2016). Both molecular (polymerase chain
reaction (PCR)) and classical microbiological tests (OIE, 2016) can be used for identifying bacterial
isolates. The only vaccine strain available (B. melitensis Rev.1) can be readily distinguished from their
corresponding B. melitensis ﬁeld counterparts as well as from B. ovis by both PCR and classical tests.
However, since only the indirect tests are used for surveillance/eradication, comments on diagnostic
performance (diagnostic sensitivity (DSe) and diagnostic speciﬁcity (DSp)) will be focused to the
immunological tests.
B. ovis serological tests differ in practical aspects as well as in DSe and DSp (for a review see
Blasco (1990, 2010)). The most effective and widely used are the CFT, the AGID and the I-ELISA. The
hot saline (HS) extract of B. ovis is the recommended antigen for these B. ovis tests (OIE, 2016). Its
water solubility and high content in relevant epitopes explain its good performance. However, in areas
where B. melitensis infection also exists or Rev.1 vaccination is applied, the speciﬁcity of the OIE/EU
B. ovis tests with HS antigen has to be carefully interpreted taking into account the results of
B. melitensis tests (Blasco, 2010). Despite being the only OIE/EU ofﬁcially recognised test, CFT has
important disadvantages such as complexity, obligatory serum inactivation, anticomplementary activity
in some sera, the impossibility of testing haemolysed sera and prozones. Moreover, comparative
studies have shown that, provided an adequate validation is performed, the ELISA has a better
sensitivity than either the AGID or the CFT (Gall et al., 2003; Blasco, 2010; Praud et al., 2012; OIE,
2016). However, due to the existence of ELISA-negative but CFT- (or AGID)-positive sera and vice
versa, the parallel combination of the CFT (or AGID) and ELISA results in optimal diagnostic
performance (Blasco, 2010; Praud et al., 2012). Because of their sensitivity, simplicity and easy
interpretation, both the ELISA and AGID test would be preferred for surveillance in low-prevalence
zones.
Little is known about false-positive results in these HS B. ovis tests. The foot rot agent
(Dichelobacter nodosus) has been described as cross-reacting with B. ovis, but the extent and practical
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consequences in B. ovis tests are not well understood (Blasco, 2010; OIE, 2016). In addition,
Arcanobacterium pyogenes and Corynebacterium ovis soluble extracts cross-react with sera from
B. ovis-infected rams, being both pathogens isolated from rams resulting positive in B. ovis tests
(Blasco, 2010). The brucellin skin test could also be used to test unvaccinated sheep against B. ovis
(Velasco et al., 1997). This allergen test could be adequate when suspecting false positive serological
reactions, but suitable studies proving its DSe and DSp for B. ovis diagnosis are lacking.
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
A large variety of samples can be collected for culture. Milk samples and vaginal swabs from
aborted sheep, and semen and preputial swabs taken from rams are particularly useful for
bacteriological diagnosis in live animals. B. ovis can also be cultured from aborted fetuses or the
placenta. The spleen, whole lymph nodes and late pregnant or early post-parturient uterus, testis/
epididymides, and accessory ram sex glands are the most reliable samples to collect at necropsy (De
Miguel et al., 2011). All these samples are also suitable theoretically for direct PCR diagnostic
procedures. Several PCRs have been reported to result in good diagnostic performance when applied
to semen samples from B. ovis-infected rams (Manterola et al., 2003; Xavier et al., 2010). However,
none of these PCRs outperform the classical culture, and moreover, their diagnostic performance
remains to be properly determined on other clinical samples. Thus, the culture should be considered as
the reference standard for the bacteriological diagnosis of B. ovis (De Miguel et al., 2011; OIE, 2016).
Blood serum samples can be collected for serological diagnosis and are the preferred samples for
surveillance at large population level.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
Vaccination is considered the most effective method of control in high incidence areas (Blasco,
1990, 2010). The B. abortus S19 live-attenuated vaccine was applied many years ago to prevent
B. ovis, but it was later on abandoned because of the important side effects induced (Blasco, 1990;
Ridler and West, 2011). The B. melitensis Rev.1, a live attenuated vaccine developed for the control of
B. melitensis infection, is the only available vaccine against B. ovis infection. The vaccine is
administered via subcutaneous injection or conjunctival inoculation. Its general characteristics are
described in Table 3.
Parameter 2 – Availability/production capacity (per year)
The Rev.1 vaccine is currently produced worldwide with important regional differences. The
different manufacturing companies are shown in Table 4.
Table 3: General characteristics of the B. melitensis Rev.1 vaccine in sheep (adapted from Blasco
et al. (2016))
Advantages Disadvantages Comments
Proved efﬁcacy in B. melitensis
control/eradication programmes
(France, Italy, Portugal, Spain).
Effective against both B. melitensis
and B. ovis.
Safe in young replacements (males
and females).
Single dose affords useful
protection for life.
Biological quality control feasible
(OIE accepted)
Highly abortifacient when used in
pregnant ewes.
Serological interference in classical
serological tests (RBT, CFT),
indirect and competitive ELISAs,
ﬂuorescence polarisation assay and
other B. melitensis tests.
Serological interference in HS
B. ovis tests
Virulent (low) for humans;
streptomycin resistant
Safety issues minimised by avoiding
use in mid-pregnancy ewes by the
conjunctival route.
Serological interference minimised
when applied exclusively to young
replacement animals by the
conjunctival route.
Human Rev 1 infections can be
diagnosed using simple standard
serological tests; treatment requires
regimes avoiding streptomycin
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As a consequence of the effective B. melitensis ofﬁcial eradication programme in sheep and goats
in most EU MS, these European manufacturing companies have reduced signiﬁcantly the overall
production capacity, which is essentially maintained for the exterior market. However, manufacturing
technology is currently well implemented and the production capacity of these companies could be
signiﬁcantly increased to cover an emergency situation, at least in the medium term. Since Rev.1
vaccine is not protected by patents and the master seed strain can be easily obtained from several
sources (e.g. OIE or EU reference laboratories), it is marketed at relatively low cost (EUR 0.05–0.20
per dose, depending on the manufacturing country).
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
The vaccine is safe enough for use in rams. After being inoculated by subcutaneous or conjunctival
routes in either young or adult rams, the Rev.1 strain colonises the spleen and several lymph nodes,
but despite persisting for 2–3 months in the vaccinated animals, the genital organs are not colonised
by Rev 1 (Mu~noz et al., 2008). Experimentally, 56–100% of Rev.1-vaccinated rams are protected
against a B. ovis challenge able to infect 80–100% of unvaccinated controls (Blasco, 2010). Moreover,
the genital lesions produced after challenge are signiﬁcantly less severe than in unvaccinated animals.
However, the evidence about the protection conferred by the vaccine in the ﬁeld is scanty. In a study
conducted in France between 1981 and 1989, it was reported that the vaccination with Rev.1 applied
in young replacement male and female lambs was able to reduce signiﬁcantly both the ﬂock (from
16.8% to 5%) and individual (11.9% to 4.3%) prevalences, with a vaccination coverage around 70%
of target animals (Sanchis et al., 1991). The same vaccination strategy, applied only in around 50% of
ﬂocks, was also able to reduce both ﬂock (from 32% to 14%) and individual (20% to 7%) prevalences
in only 3 years of application in other areas of France (AFSSA, 2008). Finally, it has been clearly
proven in France (Table 5) that the prevalence of B. ovis infection increases signiﬁcantly and in a very
short interval once the Rev.1 vaccination is abandoned.
Table 4: Current B. melitensis Rev.1 vaccine manufacturing companies
MANUFACTURER COUNTRY COMMERCIAL NAME ROUTE WEBSITE
AGROVET RUSSIA ND SC http://www.agrovet.ru/
ATA FEN INC TURKEY Rev.1 CJ CJ http://www.egevet.com.tr/
BIOCOMBINANT MONGOLIA ND CJ/SC
CEVA FRANCE COGLAREV CJ http://www.ceva.com/fr/
CZ VETERINARIA SPAIN OCUREV CJ http://www.czveterinaria.com/
CZ VETERINARIA CZV REV-1 SC http://www.czveterinaria.com/
DOLLVET TURKEY Brudoll M SC http://www.dollvet.com.tr/
INDIAN
IMMUNOLOGICALS
INDIA BRUVAX REV1 SC https://www.indimmune.com/
JINYU CHINA REV1
JOVAC JORDAN Brucevac CJ CJ http://www.jovaccenter.com/
Brucevac (reduced dose) SC
ONDERSTEPOORT Brucella Rev. 1 SC http://www.obpvaccines.co.za/
OVEJERO SPAIN OVERVAC OC CJ/SC http://www.labovejero.com/
PENDIK TURKEY BR.REV-1 CJ/SC http://penvet.gov.tr/
PRONAVIBE MELIREV N SC http://www.pronabive.gob.mx/
RAZI IRAN ND CJ/SC http://www.rvsri.com
SYVA SPAIN Lio Vac Rev-1 SC/CJ http://www.syva.es/
VETAL TURKEY ABORVAC R CS CJ http://www.vetal.com.tr/
VETAL ABORVAC R SC http://www.vetal.com.tr/
VETERINARY SERUM
INSTITUTE
EGYPT Rev-1 SC http://www.vsvri-eg.com/
ND: not available; CJ: conjunctival administration; SC: subcutaneous administration.
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The disadvantages of Rev.1 vaccine (Table 3) include the development of both B. melitensis and
B. ovis antibodies, which could interfere with serologic diagnosis (Blasco, 1990, 2010). Moreover, this
vaccine is prohibited for use in B. melitensis ofﬁcially free countries. Innovative vaccine approaches are
currently being investigated (for a review see Blasco et al. (2016)), which raises the possibility of more
effective vaccines in the future. For the moment, none of these new vaccine candidates are available
on the market.
Parameter 4 – Duration of protection
The precise duration of protection conferred by Rev.1 against B. ovis infection has never been
properly assessed. However, it has been proven experimentally that Rev 1 induces suitable protection
against B. melitensis in sheep for at least two consecutive pregnancies (Verger et al., 1995). The
protection lapse span of Rev.1 against B. melitensis in goats is very long going from 4 years and a half
(Alton, 1990) to 5 years (Dıaz-Aparicio et al., 2004). It is unclear whether revaccination improves the
immunity achieved with a single dose, and it is thus widely accepted that a single dose of Rev.1
confers whole-life immunity against B. melitensis (Blasco et al., 2016). It could be then accepted that
this also happens in the case of B. ovis, but ﬁeld or experimental evidences are lacking.
Feasibility
Parameter 5 – Way of administration
The B. melitensis Rev.1 vaccine can be administered to sheep (both males and females) in a single
standard dose (0.5–2 9 109 CFU) by either the subcutaneous or the conjunctival routes (OIE, 2016).
Conjunctival administration is safer than the subcutaneous route for vaccinating adult animals and
reduces signiﬁcantly the intensity and duration of the immunological response, then minimising the
interference in diagnostic tests (Blasco and Molina-Flores, 2011; Blasco et al., 2016).
3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Due to economical, epidemiological and public health reasons, treatment with antibiotics has been
generally precluded in animals infected with brucellosis. However, several therapeutic regimens have
been evaluated successfully for treating brucellosis in cattle, sheep, pigs and dogs. Several have been
applied experimentally also to treat B. ovis infection in sheep.
Parameter 1 – Types of drugs available on the market
In spite of successful antibiotic treatment of human brucellosis, this therapy has seldom been used
in animal brucellosis. The existence of eradication programmes and the high treatment costs are the
main reasons precluding the use of antibiotics in animals. There are, however, some reports on the
successful use of antibiotherapy in B. ovis infection (see below). Suitable antibiotics are largely
available on the market.
Parameter 2 – Availability/production capacity (per year)
All effective antibiotics against B. ovis (see below) are readily and sufﬁciently available worldwide.
Table 5: Evolution of the prevalence (assessed by serological tests, CFT and ELISA) of B. ovis
infection in rams in the Pyrenees-Atlantiques Departement in France, once vaccination with
Rev.1 was abandoned in the year 2000 (adapted from AFSSA (2008))
Years
2001(a) 2004(b) 2005(b) 2006(b)
Flocks tested 352 280 640 730
Rams tested (n.a.) 2,183 3,075 5,360
% ﬂocks infected (IC 95%) 8 (5.4–11.3) 34 (38.8–52.7) 38 (34.2–41.9) 30 (26.7–33.5)
% rams infected (IC 95%) 4 (n.a.) 16 (14.5–17.6) 18 (16.7–19.4) 22 (20.9–23.1)
(a): Aleatory sampling covering 10% of ﬂocks.
(b): Data obtained from voluntary owners.
(n.a.: ﬁgures not available).
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Effectiveness
Parameter 3 – Therapeutic effects on the ﬁeld (effectiveness)
It was reported many years ago that the combined use of chlortetracycline and streptomycin was able
to cure epididymitis lesions and stop semen excretion of B. ovis in artiﬁcially infected rams, but semen
quality after treatment was poor. However, streptomycin given alone or combined with sulphamethazine
failed to cure these experimentally infected rams (Kuppuswamy, 1954). In another study, 27 out of 32
B. ovis naturally infected rams were treated with a combination of chlortetracycline and streptomycin
and became serologically negative and showed no epididymitis lesions by eight months after treatment
(Giauffret and Sanchis, 1974). Likewise, a combination of long-acting oxytetracycline (seven inoculations
of 20 mg/kg body weight (BW) at three-day intervals) with dihydrostreptomycin (20 mg/kg BW daily for
21 days) was able to abrogate B. ovis semen excretion soon after treatment (Table 6; Marın et al.
(1989)). However, treatment with oxytetracycline alone did not avoid semen excretion in a relevant
proportion of infected rams. This combined treatment cured B. ovis infection in 11 out of 12 artiﬁcially
infected rams (Marın et al., 1989). In contrast, only 4 of 12 infected rams were cured when treated with
oxytetracycline alone. Additional studies should be conducted to assess the efﬁcacy of these antibiotic
treatments at ﬁeld level and to determine the full recovery of fertility in bacteriologically cured animals.
The costs of treatment and the follow-up testing schedules are very expensive, and thus, this antibiotic
therapy is only recommended for valuable rams of exceptional genetic value or belonging to endangered
breeds. Successfully treated rams remain seropositive for some time after resolution of infection, which
needs to be considered if a testing and culling programme is implemented in these animals.
Feasibility
Parameter 4 – Way of administration
Oxytetracycline long-acting solutions and the suitable aminoglycosides (streptomycin) are given
intramuscularly. Oxytetracycline is also available in soluble forms to be given orally in water or pelleted
feed; but due to potential interferences with rumen ﬂora, this approach is not recommendable for
ruminants.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
B. ovis is mainly spread via venereal transmission. Key risk factors include:
• Animals moving between and within farms and, in particular, the introduction of new animals
without ascertaining their B. ovis-free status.2
• Direct contact with neighbours’ animals/farms infected with B. ovis.
Thus, all measures avoiding these risk factors should contribute to minimise B. ovis spread between
infected and healthy ﬂocks. Biosecurity would be focused essentially on controlling and reducing
movements of animals (particularly the purchase of replacements). In addition, attention should be
paid to movement of feed, water, bedding manure, people and equipment to and from areas where
sheep are kept.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
While the above measures are feasible and effective for minimising brucellosis spread in highly
intensiﬁed farming systems, are very difﬁcult to implement in outdoor or fully extensive/transhumant
sheep breeding systems (widespread in most sheep raising countries). At least in the EU MS, rules on
zoning (see Section 3.1.4.5 Parameter 1 below and Section 3.1.5) and on restriction of animal
movements, according the available EU Directives, have been proven instrumental to minimise the
spread of B. abortus and B. melitensis infections and are also equally effective to minimise the spread
of B. ovis infection in sheep.
2 There is only an OIE deﬁnition of the B. ovis-free status of ﬂocks, but there is no EU deﬁnition of freedom. The OIE deﬁnition
is only based on the absence of clinical signs during the past year (OIE, 2017). Other countries (Australia and New Zealand for
example) certify free ﬂocks or areas.
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Feasibility
Parameter 3 – Feasibility of biosecurity measures
Biosecurity measures for avoiding the spread of brucellosis in domestic ruminants based on the
current rules on zoning and on restriction of animal movements, according the available EU Directives,
have been proven feasible and very effective.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
EU Legislation affecting animal movements and dealing with Brucella ovis infection is covered by
Council Directive 91/68/EEC3 and Council Directive 92/65/EEC4.
For importation, additional animal health requirements are set out in speciﬁc Commission Decisions
that lay down conditions applying to imports of live animals and products from third countries. The EU
legislation is fully harmonised and compliant with its international obligations and, in particular, the
requirements of the Sanitary and Phytosanitary Agreement of the WTO. This legislation imposes a
series of requirements designed to ensure that imported animals and products meet standards at least
equivalent to those required for production in and trade between MS. These lay down on health
certiﬁcates which must accompany all animal imports. On arrival in the EU, the animals and the
accompanying certiﬁcates must be veriﬁed and checked by EU ofﬁcial veterinarians at a designated
Border Inspection Post. Further checks on the animals may also be carried out at the ﬁnal destination.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between-farm spread
The existing EU Directives on the restriction of movements has been proven highly effective to
prevent the spread of Brucella infection between farms in the MS in which the disease yet exists.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
The Council Directives dealing with restrictions of animal movement (see Section 3.1.4.5 Parameter
1 above) have been successfully and feasibly implemented by MS many years ago, and proven of
paramount importance in the successful eradication of brucellosis and to reduce the spread of the
disease in the countries in which the disease is yet present. Computerised management of livestock
national and international movements constitutes a further step in the management of health hazards
associated with the movement of animals.
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
Brucellosis eradication requires the identiﬁcation of infected animals, their progressive elimination
from the herd/ﬂock and replacement with non-infected animals (Crespo Leon et al., 2012). In the case
of identifying and conﬁrming B. ovis infection in holdings belonging to MS, the slaughter of infected
animals is recommended. However, the eradication of this infection is not compulsory in MS, and no
ofﬁcial eradication programmes have been implemented compulsorily in the EU.
3 Council Directive 91/68/EEC of 28 January 1991 on animal health conditions governing intracommunity trade in ovine and
caprine animals. OJ L 46, 19.2.1991, p. 19–36.
4 Council Directive 92/65/EEC of 13 July 1992 laying down animal health requirements governing trade in and imports into the
Community of animals, semen, ova and embryos not subject to animal health requirements laid down in speciﬁc Community
rules referred to in Annex A (I) to Directive 90/425/EEC. OJ L 268, 14.9.1992, p. 54–72.
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Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
The killing of B. ovis-infected rams (identiﬁed by serological tests and clinical palpation) has been
implemented for eradicating B. ovis in sheep in several countries. Using this test and slaughter
approach, the infection has been eradicated from the Falkland Islands (Reichel et al., 1994), the
Flinders and King Islands of Australia and selected areas of New Zealand (Ridler and West, 2011).
This programme (using both the CFT and ELISA as diagnostic tests) has been also applied since
1986 in the Basque Country Autonomous Community of Spain. While initial ﬂock seroprevalence was
very high (60%), the number of infected ﬂocks was reduced signiﬁcantly although without getting a
full elimination of the disease. The number of B. ovis-infected ﬂocks decreased by 96% during the ﬁrst
10 years of the programme, but in the last 5 years reported, the ﬂock seroprevalence has remained
constant at levels of around 0.7% (Juste et al., 2013) (Figure 1 ).
Feasibility
Parameter 3 – Feasibility of killing animals
These killing measures have a wide acceptance in the EU and have been proven highly effective
and feasible after many years of application of the compulsory brucellosis eradication programmes in
the MS.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Depending on the age and health of the animal, carcasses and by-products may be disposed of
through the abattoir system or by rendering. Currently, available disposal options are considered
effective. Disposal via abattoir or rendering is already routine.
Figure 1: Evolution of the prevalence of B. ovis infection, the Basque Country Autonomous
Community in Spain, after several years of application of a testing and culling programme
(Juste et al., 2013)
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3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
There are very few well-documented studies on the production losses and ensuing economic impact
of brucellosis considering all disease aspects (see Section 3.1.2 Parameter 1). Since its real prevalence
is mostly unknown in the MS, these costs are impossible to calculate for B. ovis infection.
Nevertheless, having consideration for the epidemiology of B. ovis (non-zoonotic and having low
capacity of spreading in the short term), any unexpected local outbreak should not have important
consequences for the sector involved.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
The currently applied culling and disposal systems used in the compulsory EU eradication
programmes for animal brucellosis (B. abortus and B. melitensis infection) were implemented many
years ago and have been widely accepted by the affected owners and the overall society. In the event
that a B. ovis eradication programme based on testing and culling was introduced compulsorily in the
EU MS, it should be well accepted by the owners and the general society.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Whenever properly managed by competent veterinarians, the measures implemented for controlling
brucellosis (usually through vaccination) do not pose any relevant issue from the animal welfare
standpoint. Moreover, eradication measures (based on the partial culling of infected animals combined
or not with vaccination) have been and continue being instrumental for the successful brucellosis
eradication programmes applied in the EU and elsewhere. Since 2013 in the EU is of compulsory
application the Council Regulation (EC) No 1099/20095, which establishes the protection of animals at
the moment of slaughter. This rule indicates that in the case of depopulation of holdings, it is the
obligation of competent authorities to preserve the welfare of the affected animals.
Parameter 2 – Wildlife depopulation as control measure
This is not an issue in the case of B. ovis infection since wild animals are very rarely affected
(Section 3.1.1) and, in the case of sporadic infections, this does not have any epidemiological
signiﬁcance.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
No drugs/chemicals other than the common and legally accepted antibiotics and disinfectants are
used in the current control/eradication campaigns in the EU.
Biodiversity
Parameter 2 – Mortality in wild species
The preventive and control measures for B. ovis infection do not have any impact on wildlife.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about ovine epididymitis (B. ovis) (Table 6). The expert judgement was based on Individual and
Collective Behavioural Aggregation (ICBA) approach described in detail in the opinion on the
methodology (EFSA AHAW Panel, 2017). Experts have been provided with information of the disease
fact sheet mapped into Article 5 criteria (see supporting information, Annex A), based on that the
5 Council Regulation (EC) No 1099/2009 of 24 September 2009 on the protection of animals at the time of killing. OJ L 303,
18.11.2009, p. 1–30.
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experts indicate their Y/N or ‘na’ judgement on each criterion of Article 5, and the reasoning
supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
3.2.1. Outcome of the assessment of ovine epididymitis (Brucella ovis) according
to criteria of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 6, ovine
epididymitis (B. ovis) complies with all criteria of the ﬁrst set and with two criteria of the second set;
therefore, it is considered eligible to be listed for Union intervention as laid down in Article 5(3) of the
AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about ovine epididymitis (B. ovis) (Tables 7–11). The expert
judgement was based on ICBA approach described in detail in the opinion on the methodology.
Experts have been provided with information of the disease fact sheet mapped into Article 9 criteria
(see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement
on each criterion of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 6: Outcome of the expert judgement on the Article 5 criteria for ovine epididymitis (Brucella
ovis)
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
N
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No).
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Table 7: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for ovine epididymitis (Brucella ovis) (CI: current impact; PI:
potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union or present only in exceptional
cases (irregular introductions) or present only in a very limited part of the territory of
the Union
N
2.1 The disease is highly transmissible N
2.2 There are possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects multiple species of kept and wild animals or single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential or possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease or due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease or due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No).
Table 8: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for ovine epididymitis (Brucella ovis) (CI: current impact; PI:
potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole or part of the Union territory with an endemic
character and (at the same time) several Member States or zones of the Union are free
of the disease
Y
2.1 The disease is moderately to highly transmissible Y
2.2 There are possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality Y
AHL assessment on ovine epididymitis (Brucella ovis)
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2017;15(10):4994
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential or possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease or due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease or due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No).
Table 9: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for ovine epididymitis (Brucella ovis) (CI: current impact; PI:
potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole or part of the Union territory with an endemic
character
Y
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
and often the most observed effect of the disease is production loss
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
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3.3.1. Outcome of the assessment of criteria in Annex IV for ovine epididymitis
(Brucella ovis) for the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 7–11. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for ovine epididymitis
(B. ovis) for the purpose of categorisation as in Article 9 of the AHL is presented in Table 12.
Table 10: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for ovine epididymitis (Brucella ovis)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease or due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease or due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No).
Table 11: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for ovine epididymitis (Brucella ovis)
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment
(If a disease fulﬁls the criteria as in Article 5, thus being eligible to be listed, consequently
category E would apply.)
Y
Colour code: green = consensus (Yes/No).
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According to the assessment here performed, ovine epididymitis (B. ovis) complies with the
following criteria of the Sections 1–5 of Annex IV of the AHL for the application of the disease
prevention and control rules referred to in points (a)–(e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment ovine epididymitis (B. ovis) complies only with
criterion 2.3. To be eligible for category A, a disease needs to comply additionally with one of
the criteria of the second set (3, 4, 5a–d) and ovine epididymitis (B. ovis) complies with
criteria 4 and 5b, but not with criteria 3, 5a, 5c and 5d.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment, ovine epididymitis (B. ovis) complies with
criteria 1, 2.1, 2.3 and 2.4, but not with criterion 2.2. To be eligible for category B, a disease
needs to comply additionally with one of the criteria of the second set (3, 4, 5a–d) and ovine
epididymitis (B. ovis) complies with criteria 4 and 5b, but not with criteria 3, 5a, 5c and 5d.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment, ovine epididymitis (B. ovis) complies with all
of them. To be eligible for category C, a disease needs to comply additionally with one of the
criteria of the second set (3, 4, 5a–d) and ovine epididymitis (B. ovis) complies with criterion
5b, but not with criteria 3, 4, 5a, 5c and 5d.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which ovine
epididymitis (B. ovis) complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which ovine
epididymitis (B. ovis) complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about ovine
epididymitis (B. ovis). The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
Table 12: Outcome of the assessment of criteria in Annex IV for ovine epididymitis (Brucella ovis)
for the purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.6 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for ovine epididymitis (B. ovis)
according to the criteria of Article 8(3) of the AHL are as displayed in Table 13.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, ovine epididymitis (B. ovis) complies with all
criteria of the ﬁrst set and with two criteria of the second set and therefore can be considered
eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, ovine epididymitis (B. ovis) meets the criteria as
in Sections 3, 4 and 5 of Annex IV of the AHL, for the application of the disease prevention
and control rules referred to in points (c), (d) and (e) of Article 9(1) of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of
animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for ovine epididymitis (B. ovis) according to Article 8(3) of the AHL are mainly sheep and
other species of the families Bovidae and Cervidae as susceptible and sheep and deer as
reservoirs, as reported in Table 13 in Section 3.4 of the present document.
References
AFSSA (Agence francaise de securite sanitaire des aliments), 2008. Avis de l’Agence francaise de securite sanitaire
des aliments sur un protocole de lutte contre l’epididymite contagieuse ovine (Brucella ovis) dans les Pyrenees
Atlantiques. Saisine no. 2007-SA-0405. 14 pp. Available online: https://www.anses.fr/fr/system/files/
SANT2007sa0405.pdf
Table 13: Main animal species to be listed for ovine epididymitis (Brucella ovis) according to criteria
of Article 8 (source: data reported in Section 3.1.1.1)
Class Order Family Genus/Species
Susceptible Mammalia Artiodactyla Bovidae Sheep (Ovis aries), goat (Capra hircus),
bighorn sheep (Ovis canadensis canadensis),
mouﬂon (Ovis musimon)
Cervidae White-tailed deer (Odocoileus virginianus),
red deer (Cervus elaphus elaphus)
Lagomorpha Leporidae not speciﬁed
Rodentia Muridae Rattus spp., gerbils (Gerbillinae), Mus spp.
Cricetidae Hamsters (Cricetinae)
Caviidae Guinea pig (Cavia porcellus)
Reservoir Mammalia Artiodactyla Bovidae Sheep (Ovis aries)
Cervidae(a) White-tailed deer (Odocoileus virginianus),
red deer (Cervus elaphus elaphus)
Vectors none
(a): Possibly.
6 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
AHL assessment on ovine epididymitis (Brucella ovis)
www.efsa.europa.eu/efsajournal 26 EFSA Journal 2017;15(10):4994
Alton G, 1990. Brucella melitensis 1887 to 1987. In: Nielsen KH, Duncan JR (eds.). Animal Brucellosis. CRC Press,
Boca Raton, FL. pp. 379–409.
AQIS (Australian Quarantine and Inspection Service), 2000. An analysis of the disease risks, other than Scrapie,
associated with the importation of ovine and caprine semen and embryos from Canada, the USA and member
states of the European Union. Final Report. 67 pp. Available online: http://www.agriculture.gov.au/Site
CollectionDocuments/ba/memos/2000/animal/00-038b.pdf.
Bailey K, 1997. Naturally acquired Brucella ovis infection in a deer. Surveillance, 24, 10–11.
Beauvais W, Musallam I and Guitian J, 2016. Vaccination control programs for multiple livestock host species:
an age-stratiﬁed, seasonal transmission model for brucellosis control in endemic settings. Parasites & Vectors,
9, 55.
Blasco JM, 1990. Brucella ovis. In: Nielsen KH and Duncan JR (eds). Animal Brucellosis. CRC Press, Boca Raton,
FL. pp. 352–378.
Blasco JM, 2002. Brucelosis ovina. Ovis, 82, 113.
Blasco JM, 2010. Brucella ovis infection. In: Lefevre PC, Blancou J, Chermette R and Uilenberg G (eds). Infectious
and Parasitic Diseases of Livestock. Lavoisier, Paris, France. pp. 1047–1063.
Blasco JM and Molina-Flores B, 2011. Control and eradication of Brucella melitensis infection in sheep and goats.
Veterinary Clinics of North America: Food Animal Practice, 27, 95–104.
Blasco JM, Moreno E and Moriyon I, 2016. Brucellosis vaccines and vaccine candidates. In: Metwally S, Viljoen GJ,
El Idrissi A (eds.). Veterinary Vaccines for Developing Countries. FAO, Rome, Italy. pp. 1–33.
Burgess GW, Spencer TL and Norris MJ, 1985. Experimental infection of goats with Brucella ovis. Australian
Veterinary Journal, 62, 262–264.
Carpenter T, Berry SL and Glenn JS, 1987. Economics of Brucella ovis control in sheep: computerized decision-tree
analysis. Journal of the American Veterinary Medical Association, 190, 983–987.
Cerri D, Ambrogi C, Ebani VV, Poli A, Cappelli F, Cardini G and Andreani E, 2002. Experimental Brucella ovis
infection in mouﬂon (Ovis musimon). Journal of Wildlife Diseases, 38, 287–290.
CFSPH (Center for Food Security & Public Health), 2016. Animal Disease From Potential Bioterrorist Agent.
Available online: http://www.cfsph.iastate.edu/Products/resources/WallChart.pdf
Clapp KH, Keogh J and Richards MH, 1962. Epidemiology of ovine brucellosis in South Australia. Australian
Veterinary Journal, 38, 482–486.
Collier JR and Molello JA, 1964. Comparative distribution of Brucella abortus, Brucella melitensis and Brucella ovis
in experimentally infected pregnant sheep. American Journal of Veterinary Research, 25, 930–934.
Crespo Leon F, Saez Llorente JL, Reviriego Gordejo FJ, Rodrıguez Ferri EF and Duran Ferrer M, 2012.
Complementary tools for the control and eradication of caprine and ovine brucellosis in the European Union.
Revue Scientiﬁque et Technique (International Ofﬁce of Epizootics), 31, 985–996.
CRS (Congressional Research Service), 2007. CRS Report for Congress. Agroterrorism: Threats and Preparedness.
63 pp. Available online: https://fas.org/sgp/crs/terror/RL32521.pdf.
De Miguel MJ, Marın CM, Mu~noz PM, Dieste L, Grillo MJ and Blasco JM, 2011. Development of a selective culture
medium for primary isolation of the main Brucella species. Journal of Clinical Microbiology, 49, 1458–1463.
Dıaz-Aparicio E, Hernandez L and Suarez-G€uemes F, 2004. Protection against brucellosis in goats, ﬁve years after
vaccination with reduced-dose of Brucella melitensis Rev 1 vaccine. Tropical Animal Health and Production, 36,
117.
EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare), More S, Bøtner A, Butterworth A, Calistri P, Depner
K, Edwards S, Garin-Bastuji B, Good M, Gortazar Schmidt C, Michel V, Miranda MA, Nielsen SS, Raj M, Sihvonen
L, Spoolder H, Stegeman JA, Thulke H-H, Velarde A, Willeberg P, Winckler C, Baldinelli F, Broglia A, Candiani D,
Gervelmeyer A, Zancanaro G, Kohnle L, Morgado J and Bicout D, 2017. Scientiﬁc opinion on an ad hoc method
for the assessment on listing and categorisation of animal diseases within the framework of the Animal Health
Law. EFSA Journal 2017;15(5):4783, 42 pp. https://doi.org/10.2903/j.efsa.2017.4783.
Gall D, Nielsen K, Vigliocco A, Smith P, Perez B, Rojas X and Robles C, 2003. Evaluation of an indirect enzyme-
linked immunoassay for presumptive serodiagnosis of Brucella ovis in sheep. Small Ruminant Research, 48,
173–179.
Garcıa-Carrillo C, Casas-Olascoaga R, Cuba-Caparo A, Lucero N and Szyfres B, 1977. Infeccion experimental de
caprinos machos con Brucella ovis. Estudio bacteriologico, serologico e histopatologico. Revista Argentina de
Microbiologıa, 9, 101–108.
Giauffret A and Sanchis R, 1974. Etude d’un foyer d’epididymite contagieuse du belier. Eradication de la maladie.
Bulletin - Ofﬁce International Des Epizooties, 82, 581–586.
Grillo MJ, Marın CM, Barberan M and Blasco JM, 1999. Experimental Brucella ovis infection in pregnant ewes.
Veterinary Record, 144, 555–558.
Hou Q and Sun X-D, 2016. Modelling sheep brucellosis transmission with a multi-stage model in Changling County
of Jilin Province, China. Journal of Applied Mathematics and Computing, 51, 227–244.
Juste RA, Leginagoikoa I, Villoria M, Minguijon E, Elguezabal N, Boix C, Arrazola I, Perez K and Gonzalez L, 2013.
Control of brucellosis and of respiratory Small Ruminant Lentivirus infection in small ruminants in the Basque
country, Spain. Small Ruminant Research, 110, 115–119.
AHL assessment on ovine epididymitis (Brucella ovis)
www.efsa.europa.eu/efsajournal 27 EFSA Journal 2017;15(10):4994
Kimberling CV, Parsons GA, Parsons J and Cunningham W, 2010. Ram Epididymitis. Available online: http://www.
optimalag.com/cleonscorner/Article002.aspx
Kuppuswamy PB, 1954. Chemotherapy of brucellosis in rams. New Zealand Veterinary Journal, 2, 110–118.
Liberona H and Christiansen H, 1983. A cost-beneﬁt study of an eradication scheme for Brucella ovis in sheep. OIE
Technical Series, 3, 215–223.
Manterola L, Tejero-Garces A, Ficapal A, Shopayeva G, Blasco JM, Marın CM and Lopez-Go~ni I, 2003. Evaluation of
a PCR test for the diagnosis of Brucella ovis infection in semen samples from rams. Veterinary Microbiology, 92,
65–72.
Marco J, Gonzalez L, Cuervo LA, Beltran de Heredia F, Barberan M, Marın C and Blasco JM, 1994. Brucella ovis
infection in two ﬂocks of sheep. Veterinary Record, 135, 254–256.
Marın CM, Jimenez de Bagues MP, Barberan M and Blasco JM, 1989. Efﬁcacy of long-acting oxytetracycline alone
or in combination with streptomicin for treatment of Brucella ovis infection of rams. American Journal of
Veterinary Research, 50, 560–563.
Maves RC, Castillo R, Guillen A, Espinosa B, Meza R, Espinoza N, Nu~nez G, Sanchez L, Chacaltana J, Cepeda D,
Gonzalez S and Hall ER, 2011. Antimicrobial susceptibility of Brucella melitensis isolates in Peru. Antimicrobial
Agents and Chemotherapy, 55, 1279–1281.
McCollum M, Rhyan J, Coburn S, Ewalt D, Lahr C, Nol P, Keefe T, Kimberling C and Salman M, 2013. Clinical,
culture, serology and histopathology outcomes of bighorn sheep experimentally infected with Brucella ovis.
Journal of Wildlife Diseases, 49, 900–910.
Moreno E, 1998. Genome evolution within the alpha Proteobacteria: why do some bacteria not possess plasmids
and others exhibit more than one different chromosome? FEMS Microbiology Reviews, 22, 255–275.
Morris CA, 2007. A review of genetic resistance to disease in Bos taurus cattle. Veterinary Journal, 174, 481–491.
Muhammed SI, Lauerman LH, Mesﬁn GM and Otim CP, 1975. Duration of Brucella ovis infection in ewes. The
Cornell Veterinarian, 65, 221–227.
Mu~noz PM, De Miguel MJ, Grillo MJ, Marın CM, Barberan M and Blasco JM, 2008. Immunopathological responses
and kinetics of Brucella melitensis Rev 1 infection after subcutaneous or conjunctival vaccination in rams.
Vaccine, 26, 2562–2569.
OIE (World Organization for Animal Health), 2016. Infection with Brucella ovis. In: Manual of Diagnostic Tests and
Vaccines for Terrestrial Animals.
OIE (World Organization for Animal Health), 2017. Ovine epididymitis (Brucella ovis). In: Terrestrial Animal Health
Code.
Picard-Hagen N, Berthelot X, Champion JL, Eon L, Lyazrhi F, Marois M, Peglion M, Schuster A, Trouche C and
Garin-Bastuji B, 2015. Contagious epididymitis due to Brucella ovis: relationship between sexual function,
serology and bacterial shedding in semen. BMC Veterinary Research, 11, 125.
Plant JW, Eamens GJ and Seaman JT, 1986. Serological, bacteriological and pathological changes in rams following
different routes of exposure to Brucella ovis. Australian Veterinary Journal, 63, 409–412.
Praud A, Champion JL, Corde Y, Drapeau A, Meyer L and Garin-Bastuji B, 2012. Assessment of the diagnostic
sensitivity and speciﬁcity of an indirect ELISA kit for the diagnosis of Brucella ovis infection in rams. BMC
Veterinary Research, 8, 68.
Reichel MP, Baber DJ, Armitage PW, Lampard D, Whitley RS and Hilbink F, 1994. Eradication of Brucella ovis from
the Falkland Islands 1977–1993. Veterinary Record, 134, 595–597.
Ridler AL and West DM, 2011. Control of Brucella ovis infection in sheep. Veterinary Clinics of North America: Food
Animal Practice, 27, 61–66.
Ridler AL, West DM, Stafford KJ, Wilson PR and Fenwick SG, 2000. Transmission of Brucella ovis from rams to red
deer stags. New Zealand Veterinary Journal, 48, 57–59.
Ridler AL, West DM and Collett MG, 2012. Pathology of Brucella ovis infection in red deer stags (Cervus elaphus).
New Zealand Veterinary Journal, 60, 146–149.
Sanchis R, Abadie G and Polveroni G, 1991. Evolution de l’epididymite contagieuse du belier a Brucella ovis dans
les Alpes-Maritimes. Inﬂuence de l’utilisation du vaccin Rev. 1. Bulletin De l’Academie Veterinaire De France, 23,
35–40.
Sergeant ES, 1994. Seroprevalence of Brucella ovis infection in commercial ram ﬂocks in the Tamworth area. New
Zealand Veterinary Journal, 42, 97–100.
The Australia Group, online, 2017. List of human and animal pathogens and toxins for export control. Available
online: http://www.australiagroup.net/en/human_animal_pathogens.html
Velasco J, Dıaz R, Grillo MJ, Barberan M, Marın C, Blasco JM and Moriyon I, 1997. Antibody and delayed-type
hypersensitivity responses to Ochrobactrum anthropi cytosolic and outer membrane antigens in infections by
smooth and rough Brucella spp. Clinical and Diagnostic Laboratory Immunology, 4, 279–284.
Verger JM, Grayon M, Zundel E, Lechopier P and Olivier-Bernardin V, 1995. Comparison of the efﬁcacy of Brucella
suis strain 2 and Brucella melitensis Rev 1 live vaccines against a Brucella melitensis experimental infection in
pregnant ewes. Vaccine, 13, 191–196.
Xavier MN, Silva TM, Costa EA, Paix~ao TA, Moustacas VS, Carvalho CA, Sant’Anna FM, Robles CA, Gouveia AM,
Lage AP, Tsolis RM and Santos RL, 2010. Development and evaluation of a species-speciﬁc PCR assay for the
detection of Brucella ovis infection in rams. Veterinary Microbiology, 145, 158–164.
AHL assessment on ovine epididymitis (Brucella ovis)
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2017;15(10):4994
Abbreviations
AGID agar gel immunodiffusion test
AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
BW body weight
CFSPH Center for Food Security and Public Health
CFT complement ﬁxation test
CFU colony forming units
CITES Convention on International Trade in Endangered Species
DSe diagnostic sensitivity
DSp diagnostic speciﬁcity
ELISA enzyme-linked immunosorbent assay
HS hot saline
ICBA Individual and Collective Behavioural Aggregation
I-ELISA indirect enzyme-linked immunosorbent assay
IUCN International Union for Conservation of Nature
MS Member State
OIE World Organization for Animal Health
PCR polymerase chain reaction
ToR Terms of Reference
WTO World Trade Organization
AHL assessment on ovine epididymitis (Brucella ovis)
www.efsa.europa.eu/efsajournal 29 EFSA Journal 2017;15(10):4994
Annex A – Mapped fact-sheet used in the individual judgement on ovine
epididymitis (Brucella ovis)
Annex A can be found in the online version of this output (‘Supporting information’ section):
https://doi.org/10.2903/j.efsa.2017.4994
AHL assessment on ovine epididymitis (Brucella ovis)
www.efsa.europa.eu/efsajournal 30 EFSA Journal 2017;15(10):4994
